Target Name	Label	First Approval Drug	Drug Type	Disease	1922	1923	1924	1925	1926	1927	1928	1929	1930	1931	1932	1933	1934	1935	1936	1937	1938	1939	1940	1941	1942	1943	1944	1945	1946	1947	1948	1949	1950	1951	1952	1953	1954	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Progesterone receptor	Human/Protein	Norethindrone	Small molecule	Genit	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Norethindrone": "https://www.fpa.org.uk/factsheets/contraception-past-present-future; https://www.plannedparenthood.org/files/1514/3518/7100/Pill_History_FactSheet.pdf"}})	P4 (1||{"P4": {"Norethindrone": "https://drugs.ncats.io/drug/T18F433X4S; https://www.fpa.org.uk/factsheets/contraception-past-present-future; https://www.plannedparenthood.org/files/1514/3518/7100/Pill_History_FactSheet.pdf"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Interleukin-1 receptor type 1	Human/Protein	Anakinra	Protein drug	Bone	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	P2 (1||{"P2": {"Anakinra": "NCT00037648"}})	P4 (1||{"P4": {"Anakinra": "BLA103950; NCT00037648"}})	.	.
Angiotensin-converting enzyme	Human/Protein	Captopril	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Captopril": "PMID: 6985575||The early blood pressure and hemodynamic effects of the converting enzyme inhibitor (CEI), captopril, were compared in 23 hypertensive patients with those of a specific angiotensin II antagonist (AA), (Sar1, Thr8) A II, AA reduced mean arterial pressure (MAP) > 10 mm Hg only in seven of 23 patients vs 15 of 23 who responded to CEI (p<0.02)."}})	?P1	P4 (1||{"P4": {"Captopril": "NDA018343"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sodium-dependent noradrenaline transporter	Human/Protein	Imipramine	Small molecule	Mental	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Imipramine": "PMID: 1104034||Imipramine was first used clinically by Kuhn in 1957, and many controlled trials of its suggested value in the treatment of depression have been reported since in 1957, and many controlled trials of its suggested value in the treatment of depression have been reported since."}})	?P1	P4 (1||{"P4": {"Imipramine": "NDA011836"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sodium-dependent serotonin transporter	Human/Protein	Imipramine	Small molecule	Mental	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Imipramine": "PMID: 1104034||Imipramine was first used clinically by Kuhn in 1957, and many controlled trials of its suggested value in the treatment of depression have been reported since in 1957, and many controlled trials of its suggested value in the treatment of depression have been reported since."}})	?P1	P4 (1||{"P4": {"Imipramine": "NDA011836"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Erythropoietin receptor	Human/Protein	Epoetin alpha	Protein drug	Hema	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1/P2 (1||{"P1/P2": {"Epoetin alpha": "https://en.wikipedia.org/wiki/Erythropoietin#History||Synthetic EPO was first successfully used to correct anemia in 1987.; PMID: 3537801||Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial."}})	.	P4 (1||{"P4": {"Epoetin alpha": "BLA103234"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Amine oxidase [flavin-containing] B	Human/Protein	Selegiline hydrochloride	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Selegiline hydrochloride": "https://en.wikipedia.org/wiki/Selegiline#History||In 1987 Somerset Pharmaceuticals in New Jersey, which had acquired the US rights to develop selegiline, filed a new drug application (NDA) with the FDA to market the drug for PD in the US."}})	?P1	P4 (2||{"P2": {"Omacetaxine mepesuccinate": "PMID: 2914287||Phase II Study of Low-Dose Continuous Infusion Homoharringtonine in Refractory Acute Myelogenous Leukemia"}, "P4": {"Selegiline hydrochloride": "NDA019334"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Alpha-1A adrenergic receptor	Human/Protein	Prazosin hydrochloride	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Prazosin hydrochloride": "PMID: 152750||A preliminary clinical trial of Prazosin: a new oral antihypertensive agent."}})	P1 (1||{"P1": {"Labetalol hydrochloride": "PMID: 53581||Letter: Intravenous labetalol in severe hypertension."}})	P4 (1||{"P4": {"Prazosin hydrochloride": "NDA017442"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Alpha-1B adrenergic receptor	Human/Protein	Prazosin hydrochloride	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Prazosin hydrochloride": "PMID: 152750||A preliminary clinical trial of Prazosin: a new oral antihypertensive agent."}})	P1 (1||{"P1": {"Labetalol hydrochloride": "PMID: 53581||Letter: Intravenous labetalol in severe hypertension."}})	P4 (1||{"P4": {"Prazosin hydrochloride": "NDA017442"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Alpha-1D adrenergic receptor	Human/Protein	Prazosin hydrochloride	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Prazosin hydrochloride": "PMID: 152750||A preliminary clinical trial of Prazosin: a new oral antihypertensive agent."}})	P1 (1||{"P1": {"Labetalol hydrochloride": "PMID: 53581||Letter: Intravenous labetalol in severe hypertension."}})	P4 (1||{"P4": {"Prazosin hydrochloride": "NDA017442"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Tubulin beta	Human/Protein	Paclitaxel	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Colchicine": "NCT00004368"}})	?P1	P4 (2||{"P4": {"Paclitaxel": "NDA020262"}, "P1": {"Vinorelbine": "PMID: 1327022"}})	.	.	.	.	.	.	.	.	.	.	.
BCR-ABL tyrosine kinase	Human/Protein	Imatinib mesylate	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Imatinib mesylate": "https://www.pagepress.org/journals/index.php/hmr/article/viewFile/277/185||Imatinib, the first clinically viable Abl kinase inhibitor, is the result of a medicinal chemistry project initiated by Ciba Geigy (now Novartis) in the early 1990s, with protein kinase C as the initial target. Phase I studies started in June 1998 and established the efficacy of imatinib in patients with CML in all phases.; PMID: 11870247"}})	?P1	P3 (1||{"P3": {"Imatinib mesylate": "NCT00009906"}})	P4 (1||{"P4": {"Imatinib mesylate": "NDA021335"}})	.	.
PDGF receptor	Human/Protein	Imatinib mesylate	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Imatinib mesylate": "https://www.pagepress.org/journals/index.php/hmr/article/viewFile/277/185||Imatinib, the first clinically viable Abl kinase inhibitor, is the result of a medicinal chemistry project initiated by Ciba Geigy (now Novartis) in the early 1990s, with protein kinase C as the initial target. Phase I studies started in June 1998 and established the efficacy of imatinib in patients with CML in all phases.; PMID: 11870247"}})	?P1	P3 (1||{"P3": {"Imatinib mesylate": "NCT00009906"}})	P4 (1||{"P4": {"Imatinib mesylate": "NDA021335"}})	.	.
Mineralocorticoid receptor	Human/Protein	Spironolactone	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"SC 8109": "PMID: 14409470||The aldosterone antagonist, SC-8109, was administered to a patient with clinical and biochemical evidence suggesting mineralocorticoid excess."}})	?P1	.	P4 (1||{"P4": {"Spironolactone": "NDA012151"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Muscarinic acetylcholine receptor M3	Human/Protein	Tolterodine tartrate	Small molecule	Genit	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Tolterodine tartrate": "PMID: 9121357||In the first clinical phase I study, tolterodine was given as single oral doses (0.2-12.8mg) to healthy volunteeers."}})	?P1	.	P4 (1||{"P4": {"Tolterodine tartrate": "NDA020771"}})	.	.	.	.	.
Dopamine D3 receptor	Human/Protein	Haloperidol	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Haloperidol": "American Journal of Psychiatry 1964;121:592‐4. "}})	?P1	.	P4 (1||{"P4": {"Haloperidol": "NDA015921"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Type-1 angiotensin II receptor	Human/Protein	Losartan Potassium	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Losartan Potassium": "NCT00882440; PMID:8583479; PMID: 1290620||Losartan is the first nonpeptide orally active Ang II receptor antagonist to reach clinical trials.; PMID:8583479||Discovery of losartan, the first angiotensin II receptor antagonist.; PMID: 1290620||The nonpeptide angiotensin II (All)-receptor antagonist losartan is a selective blocker of the pressor effects of AIL It is now being evaluated as an antihypertensive drug in multicenter clinical trials in the United States and other countries. Preliminary inpatient studies have shown that after 5 days of treatment, losartan—in doses of 50,100, and 150 mg — is significantly more effective than placebo in decreasing blood pressure, and has efficacy similar to that of the angiotensin-converting enzyme (ACE) inhibitor enalapril."}})	?P1	P2 (2||{"P2": {"Candesartan cilexetil": "PMID: 7884583||Open Clinical Studies on a New Angiotensin II Receptor Antagonist, TCV 116"}, "P1": {"Valsartan": "PMID: 7867676||Angiotensin II Receptor Blockade With Single Doses of Valsartan in Healthy, Normotensive Subjects"}})	P4 (2||{"P1": {"Irbesartan": "PMID: 7721404||Short-term and Sustained Renal Effects of Angiotensin II Receptor Blockade in Healthy Subjects"}, "P4": {"Losartan Potassium": "NDA020386"}})	.	.	.	.	.	.	.	.
Androgen receptor	Human/Protein	Testosterone	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Cyproterone": "https://www.fertstert.org/article/S0015-0282(16)49873-0/pdf||The antiandrogen cyproterone acetate (CPA) was first used clinically by Hammerstein and Cup- ceancu."}})	?P1	.	P4 (1||{"P4": {"Testosterone": "ANDA080911"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Gonadotropin-releasing hormone receptor	Human/Protein	Leuprolide acetate	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Leuprolide acetate": "PMID: 6354840||d-Leu-6-LH-RH-EA was administered intramuscularly for 90 days at a daily dose of 5 µg (four patients), 10 µg (four patients), 20 µg (five patients), and 200 µg (four patients)."}})	P2 (1||{"P2": {"Leuprolide acetate": "PMID: 6810559||From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents||reference 51:Harvey HA, Lipton A, Santen RJ, et al: Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Amer Assoc CanRes/Amer Soc Clin Oncol 22:444, 1981"}})	.	.	P4 (1||{"P4": {"Leuprolide acetate": "NDA019010"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Retinoic acid receptor gamma	Human/Protein	Tretinoin	Small molecule	Skin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Tretinoin": "PMID: 5676695||Topical vitamin A acid under occlusion was used on two cases of Darier's disease."}})	?P1	.	P4 (1||{"P4": {"Tretinoin": "NDA016921"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
5-HT 3 receptor	Human/Protein	Ondansetron	Small molecule	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"GR38032F": "PMID: 2885454||15 patients receiving cytotoxic drugs (other than cisplatin) that had previously produced nausea and vomiting refractory to first-line antiemetics were given a selective 5-HT3 receptor antagonist (GR38032F), 4 mg intravenously and 4 mg orally, immediately before chemotherapy, the oral dose being repeated 5 and 10h later."}})	?P1	.	.	P4 (1||{"P4": {"Ondansetron": "NDA020007"}})	.	.	.	.	.	.	.	.	.	.	.	.
Granulocyte colony-stimulating factor receptor	Human/Protein	Filgrastim	Protein drug	Immu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Filgrastim": "PMCID: PMC2033349||Granulocyte colony-stimulating factor (G-CSF) was the first human haemopoietic growth factor to be introduced into clinical practice; PMID: 9601125||G-CSF has had a remarkable pathway for clinical development from its introduction to clinical trials in 1987."}})	P2 (1||{"P2": {"Filgrastim": "NCT00002461||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma"}})	P2 (1||{"P2": {"Filgrastim": "NCT00002461||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma"}})	P2 (1||{"P2": {"Filgrastim": "NCT00002461||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma"}})	P4 (1||{"P4": {"Filgrastim": "BLA103353"}})	.	.	.	.	.	.	.	.	.	.	.	.
Pancreatic triacylglycerol lipase	Human/Protein	Orlistat	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Orlistat": "PMID: 7627244||The first multicenter clinical trial establishing the efficacy of orlistat was published in 1995 by Drent and colleagues.; Murphy L J. Orlistat: an update after the first decade of clinical experience[J]. Therapy, 2005, 2(1):7-12."}})	?P1	.	P2 (1||{"P2": {"Orlistat": "NCT00001723"}})	P4 (1||{"P4": {"Orlistat": "NDA020766"}})	.	.	.	.
Solute carrier family 12 member 1	Human/Protein	Furosemide	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Furosemide": "PMID: 14185657||Experience of this preparation over 22 months and with more than 80 patients is now reported, the trial substance in the United Kingdom having been known as Salu 058, now available commercially as Lasix."}})	?P1	.	.	P4 (1||{"P4": {"Furosemide": "NDA016273"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Growth hormone receptor	Human/Protein	Pegvisomant	Protein drug	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Pegvisomant": "PMID: 12090548||By September 1998, phase 1 trials of the treatment were underway for diabetic retinopathy"}})	?P1	?P1	P3 (1||{"P3": {"Pegvisomant": "NCT00017927"}})	P3 (1||{"P3": {"Pegvisomant": "NCT00017927"}})	P4 (1||{"P4": {"Pegvisomant": "NCT00068042; NDA021106"}})
Ceramide glucosyltransferase	Human/Protein	Miglustat	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Miglustat": "PMID: 17609429||In April 2000, the results of the first clinical trial with miglustat, an oral substrate inhibitor, as monotherapy in 28 adult patients with non-neuronopathic (type I) Gaucher disease were reported.; PMID: 10339597||One such inhibitor is N-butyldeoxynojirimycin, which currently is in clinical trials for the potential treatment of type 1 Gaucher disease."}})	?P1	.	P2 (1||{"P2": {"Miglustat": "NCT00041535; NCT00517153"}})	P4 (1||{"P4": {"Miglustat": "NDA021348"}})
Somatotropin	Human/Protein	Somatrem	Protein drug	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Recombinant human growth hormone": "https://en.wikipedia.org/wiki/Growth_hormone||Genentech pioneered the first use of recombinant human growth hormone for human therapy in 1981.; https://en.wikipedia.org/wiki/Growth_hormone_therapy#History||Because this was new technology, approval was deferred as lengthy safety trials continued over the next four years."}})	P2/P3 (1||{"P2/P3": {"Somatrem": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1651-2227.1987.tb17089.x"}})	.	.	P4 (1||{"P4": {"Somatrem": "NDA019107"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
26S proteasome	Human/Protein	Bortezomib	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Bortezomib": "https://www.sciencedirect.com/topics/neuroscience/bortezomib||Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans.; PMID: 10499643||PS-341 was chosen as the first representative of this new class of agents to enter the clinic and is currently under Phase I clinical evaluation.; PMID: 9766662||(Received 5/13/98)."}})	?P1	.	P2 (1||{"P2": {"Bortezomib": "NCT00023712; NCT00425503"}})	P3 (1||{"P3": {"Bortezomib": "NCT00063726; NCT00048230"}})	P4 (1||{"P4": {"Bortezomib": "NDA021602"}})
Prothrombin	Human/Protein	Lepirudin recombinant	Protein drug	Hema	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Lepirudin recombinant": "PMID: 23479835||The \"youngest\" class of anticoagulants, direct thrombin inhibitors (DTIs) bind and inhibit thrombin without involving any other coagulation protein. Hirudin, a component of Hirudo medicinalis (medicinal leech) saliva, was first described as an anticoagulant by Haycraft way back in 1884, was chemically characterized in 1976, and synthesized as lepirudin by Berlex, Ine in the 1990s. Lepirudin (Refludan ), a 65 amino acid polypeptide, was cleared by the FDA in 1998. It was indicated as a substitute for UFH in patients who had developed heparin-induced thrombocytopenia with thrombosis (HITT, HIT).9 Largely replaced by the oligopeptide bivalirudin (Angiomax ), released in 2006, lepirudin's European producer terminated its production on May 31, 2012.; PMID: 8409044||Clinical pharmacology of the intravenously administered recombinant desulfatohirudin CGP 39393 was investigated in 47 healthy volunteers in a multicenter study.(phase 1 1993)The biologic effect of recombinant desulfato-hirudin (CGP 39393) administered as single or repeated (every 8 h for 3 days or every 12 h for 6 days) subcutaneous injections was studied in 231 healthy human volunteers."}})	?P1	.	P1 (1||{"P1": {"Desirudin": "PMID: 8872129"}})	P3 (1||{"P3": {"Desirudin": "PMID: 9358126"}})	P4 (1||{"P4": {"Lepirudin recombinant": "NDA020807"}})	.	.	.	.	.
Peptidyl-prolyl cis-trans isomerase FKBP1A	Human/Protein	Tacrolimus	Small molecule	Immu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Tacrolimus": "PMID: 7693372||Experimental data were first published in 1987, and clinical trials were started 2 years later in Pittsburgh. Phase1 1999."}})	?P1	.	.	.	P4 (1||{"P4": {"Tacrolimus": "NDA050708"}})	.	.	.	.	.	.	.	.	.
Alpha-galactosidase A	Human/Protein	Agalsidase beta	Protein drug	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Agalsidase beta": "https://keionline.org/sites/default/files/Replagal_Fabrazyme_Timeline.pdf"}})	P3 (2||{"P1": {"Agalsidase alpha": "PMID: 10618424||To investigate the effects of purified a-gal A, 10 patients with Fabry disease received a single i.v. infusion of one of five escalating dose levels of the enzyme.agalsidase alfa.; PMID: 11386930||Double-blind placebo-controlled trial conducted from December 1998 to August 1999 at the Clinical Research Center of the National Institutes of Health."}, "P3": {"Agalsidase beta": "NCT00074971"}})	P3 (1||{"P3": {"Agalsidase beta": "NCT00074971"}})	P3 (1||{"P3": {"Agalsidase beta": "NCT00074971"}})	P3 (2||{"P3": {"Agalsidase beta": "NCT00074971"}, "P2": {"DRX005B": "NCT00048906"}})	P4 (2||{"P4": {"Agalsidase beta": "BLA103979; NCT00074984; NCT00196716; NCT00837824"}, "P2": {"DRX005B": "NCT00048906"}})
Interferon alpha/beta receptor	Human/Protein	Interferon alpha-2b	Protein drug	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Interferon alpha-2b": "PMID: 3542185||And the drug was approved in the United States in June 1986, less than 5 years after Phase I trials had been initiated."}})	?P1	.	.	.	P4 (2||{"P4": {"Interferon alpha-2b": "BLA103132"}, "P1": {"Interferon beta-1b": "PMID: 3014018||A total of 10 volunteers were each given a total of 2.6 X 10(7) units of IFN-beta ser as 13 doses administered three times daily over 4 days and there were negligible symptoms that were not significantly different from those in 10 given placebo. Twenty-seven volunteers were then given the same regime and challenged after the fourth dose with rhinovirus types 9 and 14. Compared with 27 volunteers given placebo and virus, there were significant reductions in the mean total clinical scores, the amount of nasal secretion, and the frequency of virus excretion."}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Histamine H2 receptor	Human/Protein	Cimetidine	Small molecule	Digest	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Burimamide": "PMID: 78160||Burimamide, the first H2 antagonist to be used in man is effective intravenously but less so orally.; PMID: 4117206||Effects in man of histamine H2 -receptor blockade by burimamide.1972."}})	?P1	.	.	.	P4 (1||{"P4": {"Cimetidine": "NDA017920"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Serine/threonine-protein kinase mTOR	Human/Protein	Sirolimus	Small molecule	Immu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Sirolimus": "PMID: 17275731; PMID: 8588237"}})	?P1	P2/P3 (2||{"P2/P3": {"Sirolimus": "NCT00328770"}, "P1": {"Temsirolimus": "NCT00002790"}})	P2/P3 (1||{"P2/P3": {"Sirolimus": "NCT00328770"}})	P2/P3 (1||{"P2/P3": {"Sirolimus": "NCT00328770"}})	P4 (1||{"P4": {"Sirolimus": "NDA021083"}})	.	.	.	.
Beta-2 adrenergic receptor	Human/Protein	Propranolol hydrochloride	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Dichloroisoprenaline": "PMID: 13948521||Effect of dichloroisoprenaline on the peripheral vascular responses to adrenaline in man.; https://en.wikipedia.org/wiki/Dichloroisoprenaline||Dichloroisoprenaline (DCI), also known as dichloroisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β1-adrenergic and β2-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors"}})	?P1	.	.	.	P4 (1||{"P4": {"Propranolol hydrochloride": "NDA016418"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Beta-1 adrenergic receptor	Human/Protein	Propranolol hydrochloride	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Dichloroisoprenaline": "PMID: 13948521||Effect of dichloroisoprenaline on the peripheral vascular responses to adrenaline in man.; https://en.wikipedia.org/wiki/Dichloroisoprenaline||Dichloroisoprenaline (DCI), also known as dichloroisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β1-adrenergic and β2-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors"}})	?P1	.	.	.	P4 (1||{"P4": {"Propranolol hydrochloride": "NDA016418"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Glucagon	Human/Protein	Glucagon hydrochloride	Protein drug	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Glucagon hydrochloride": "PMID: 13243215||Glucagon was administered to thirty-four children varying from 2 months to 13 years of age. It consistently produced a hyperglycemic effect in normal subjects."}})	?P1	.	.	.	P4 (1||{"P4": {"Glucagon hydrochloride": "NDA012122"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
GABAA receptor (benzodiazepine binding-site)	Human/Protein	Diazepam	Small molecule	Mental	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Chlordiazepoxide": "PMID: 21315551||Before being tested in humans, chlordiazepoxide was assessed in a preclinical study in leopards, lions, panthers, tigers, and pumas at the San Diego and Boston zoos: the sedative effect was described as “taming” these wild animals. This was followed in early 1958 by the clinical phases of the study of Ro 5-0690, directed by Leonard R.Hines (the Biological Research director at Roche)."}})	?P1	.	.	.	P4 (1||{"P4": {"Diazepam": "NDA013263"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Synaptic vesicle glycoprotein 2A	Human/Protein	Levetiracetam	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Levetiracetam": "PMID: 8991791||Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam."}})	?P1	.	.	.	P4 (1||{"P4": {"Levetiracetam": "NDA021035"}})	.	.	.	.
T-cell surface antigen CD2	Human/Protein	Alefacept	Protein drug	Skin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Siplizumab": "NCT00807794"}})	P1 (1||{"P1": {"Siplizumab": "NCT00807794"}})	P1 (1||{"P1": {"Siplizumab": "NCT00806208"}})	P1 (1||{"P1": {"Siplizumab": "NCT00806208"}})	P2 (1||{"P2": {"Siplizumab": "NCT00192452; NCT00540618"}})	P3 (2||{"P3": {"Alefacept": "PMID: 12451365||A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis"}, "P2": {"Siplizumab": "NCT00540618"}})	P4 (2||{"P4": {"Alefacept": "BLA125036"}, "P2": {"Siplizumab": "NCT00540618"}})
Endothelin ET-B receptor	Human/Protein	Bosentan	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Bosentan": "NCT00001527; PMID: 8197152; PMID: 12070534; PMID: 8951932||Bosentan, a specific mixed antagonist of endothelin receptors with no vasoconstrictor activity, inhibits neurogenic plasma extravasation (NPE) within rat dura mater. This would predict efficacy in aborting migraine attacks, without causing cardiovascular side-effects. We investigated the efficacy of 250 mg i.v. bosentan in a randomized, double-blind, placebo-controlled, clinical trial."}})	P1 (1||{"P1": {"Bosentan": "NCT00001527"}})	P1 (1||{"P1": {"Bosentan": "NCT00001527"}})	P2 (2||{"P1": {"Bosentan": "NCT00001527"}, "P2": {"Tezosentan": "NCT02223494"}})	P2 (2||{"P1": {"Bosentan": "NCT00001527"}, "P2": {"Tezosentan": "NCT02223494"}})	P2 (2||{"P1": {"Bosentan": "NCT00001527"}, "P2": {"Tezosentan": "NCT02223494"}})	P4 (2||{"P4": {"Bosentan": "NDA021290"}, "P3": {"Tezosentan": "https://www.medscape.com/viewarticle/783919"}})	.	.
Alpha-L-iduronidase	Human/Protein	Laronidase	Protein drug	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1/P2 (1||{"P1/P2": {"Laronidase": "PMID: 15794739||This open-label safety and efficacy study (A phase I Clinical studies with laronidase) began in 1997 and was originally designed as a 26-week study, but was extended in steps to 3 years. In addition, safety and urinary GAG data were collected for up to 5 years of treatment. "}})	.	.	P3 (1||{"P3": {"Laronidase": "NCT00912925"}})	P3 (1||{"P3": {"Laronidase": "NCT00146770; NCT00912925"}})	P3 (1||{"P3": {"Laronidase": "NCT00146770"}})	P4 (1||{"P4": {"Laronidase": "BLA125058"}})
Myeloid cell surface antigen CD33	Human/Protein	Gemtuzumab ozogamicin	Antibody	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Lintuzumab": "PMID: 8142644||A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity."}})	P2 (1||{"P2": {"Lintuzumab": "NCT00002609"}})	P2 (1||{"P2": {"Lintuzumab": "NCT00002609"}})	P2 (1||{"P2": {"Lintuzumab": "NCT00002609"}})	P2 (2||{"P2": {"Gemtuzumab ozogamicin": "NCT00003131", "Lintuzumab": "NCT00002609"}})	P2 (2||{"P2": {"Gemtuzumab ozogamicin": "NCT00003131; NCT00003673", "Lintuzumab": "NCT00002609"}})	P2 (2||{"P2": {"Gemtuzumab ozogamicin": "NCT00003131; NCT00003673", "Lintuzumab": "NCT00002609; NCT00038051"}})	P4 (3||{"P4": {"Gemtuzumab ozogamicin": "NDA021174"}, "P1/P2": {"Lintuzumab-Bi-213": "NCT00014495"}, "P3": {"Lintuzumab": "NCT00006045"}})	.	.	.
Glycoprotein IIb/IIIa receptor	Human/Protein	Abciximab	Antibody	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	?P2	?P2	P3 (1||{"P3": {"Abciximab": "NCT00269893"}})	P3 (1||{"P3": {"Abciximab": "NCT00269893"}})	P3 (3||{"P3": {"Abciximab": "NCT00269906"}, "P1": {"MK 383": "PMID: 8403299||The activity and tolerability of MK-383 were evaluated in a two-part double-blind, placebo-controlled, dose-escalation study in healthy male subjects using 1- and 4-hour intravenous infusions.", "Tirofiban hydrochloride": "PMID: 8403299"}})	P4 (1||{"P4": {"Abciximab": "BLA103575"}})	.	.	.	.	.	.	.	.	.
5-HT 1B receptor	Human/Protein	Sumatriptan succinate	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P2	?P2	?P2	P3 (1||{"P3": {"Sumatriptan succinate": "PMID: 1653142||By the end of 1989, nearly 5000 patients had been treated with sumatriptan."}})	.	P2 (1||{"P2": {"Sumatriptan succinate": "PMID: 1653141||A Placebo-Controlled Study of Intranasal Sumatriptan for the Acute Treatment of Migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group"}})	P4 (1||{"P4": {"Sumatriptan succinate": "NDA020080"}})	.	.	.	.	.	.	.	.	.	.	.
5-HT 1D receptor	Human/Protein	Sumatriptan succinate	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P2	?P2	?P2	P3 (1||{"P3": {"Sumatriptan succinate": "PMID: 1653142||By the end of 1989, nearly 5000 patients had been treated with sumatriptan."}})	.	P2 (1||{"P2": {"Sumatriptan succinate": "PMID: 1653141||A Placebo-Controlled Study of Intranasal Sumatriptan for the Acute Treatment of Migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group"}})	P4 (1||{"P4": {"Sumatriptan succinate": "NDA020080"}})	.	.	.	.	.	.	.	.	.	.	.
Alpha-1-antitrypsin	Human/Protein	Alpha-1-proteinase inhibitor	Protein drug	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Alpha-1-proteinase inhibitor": "PMID: 9387938||The disability and early mortality that can result from this disorder (Alpha-1 antitrypsin deficiency) make it entirely logical to attempt replacement of the missing serum protein fraction and potentially suitable therapy has been available for some years.; PMID: 7028785||In the present study we assessed the feasibility of reversing this biochemical defect within the lung via parenteral replacement therapy with an alpha 1-antitrypsin concentrate of normal plasma. Received for publication 2 October 1980."}})	?P1	?P1	.	.	.	.	P4 (1||{"P4": {"Alpha-1-proteinase inhibitor": "FDA"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Somatostatin receptor type 2	Human/Protein	Octreotide acetate	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Octreotide acetate": "PMID: 19842996||Since the pharmacological properties of octreotide were first described in 1982 by Bauer et al.9, clinical evaluation has consistently demonstrated.; PMID:6128648||It is currentiy undergoing preiiminary ciinicaI trial.; PMID: 7324057||Five acromegalic patients were treated preoperatively over a period of 1-4 weeks with the somatostatin analogue SMS 201-995."}})	?P1	?P1	.	.	.	.	P4 (1||{"P4": {"Octreotide acetate": "NDA019667"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Somatostatin receptor type 5	Human/Protein	Octreotide acetate	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Octreotide acetate": "PMID: 19842996||Since the pharmacological properties of octreotide were first described in 1982 by Bauer et al.9, clinical evaluation has consistently demonstrated.; PMID:6128648||It is currentiy undergoing preiiminary ciinicaI trial.; PMID: 7324057||Five acromegalic patients were treated preoperatively over a period of 1-4 weeks with the somatostatin analogue SMS 201-995."}})	?P1	?P1	.	.	.	.	P4 (1||{"P4": {"Octreotide acetate": "NDA019667"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Human/Protein	Lovastatin	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Lovastatin": "https://books.google.com/books?id=Jh49Llr2x0AC&pg=PA74&lpg=PA74&dq=lovastatin+first+clinical&source=bl&ots=9szP_MBzge&sig=RqtXLrswo80EQZOxrqko811Ywps&hl=zh-CN&sa=X&ved=0ahUKEwiF88CQypbcAhUGxoMKHfUZCNQ4FBDoAQgmMAA#v=onepage&q=lovastatin&f=false||Foreign clinical trials with lovastatin began in April 1980 but were suspended just 5 months later."}})	?P1	.	.	.	.	.	P4 (2||{"P4": {"Lovastatin": "NDA019643"}, "P3": {"Pravastatin sodium": "PMID: 3113763||New Developments in Lipid-Lowering Therapy: The Role of Inhibitors of Hydroxymethylglutaryl-Coenzyme A Reductase"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Kit tyrosine kinase	Human/Protein	Imatinib mesylate	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Ancestim": "NCT00001398; PMID: 15526160"}})	P1 (1||{"P1": {"Ancestim": "NCT00001398"}})	P1 (1||{"P1": {"Ancestim": "NCT00001398"}})	P1 (1||{"P1": {"Ancestim": "NCT00001398; NCT00001526"}})	P1 (1||{"P1": {"Ancestim": "NCT00001398; NCT00001526"}})	P2 (2||{"P2": {"Ancestim": "NCT00001750"}, "P1": {"Imatinib mesylate": "https://www.pagepress.org/journals/index.php/hmr/article/viewFile/277/185||Imatinib, the first clinically viable Abl kinase inhibitor, is the result of a medicinal chemistry project initiated by Ciba Geigy (now Novartis) in the early 1990s, with protein kinase C as the initial target. Phase I studies started in June 1998 and established the efficacy of imatinib in patients with CML in all phases.; PMID: 11870247"}})	P2 (1||{"P2": {"Ancestim": "NCT00001750"}})	P3 (2||{"P2": {"Ancestim": "NCT00001750"}, "P3": {"Imatinib mesylate": "NCT00009906"}})	P4 (2||{"P2": {"Ancestim": "NCT00001750"}, "P4": {"Imatinib mesylate": "NDA021335"}})	.	.
NPC1-like intracellular cholesterol transporter 1	Human/Protein	Ezetimibe	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"SCH 48461": "PMID: 9336320||SCH58235(Ezetimibe) is now in development. Its predecessor, SCH48461, was shown to reduce LDL cholesterol in humans by 15% (Bergman et al., 1995).; PMID: 11245855||SCH48461 was the first of this class of cholesterol absorption inhibitors to enter human clinical trials (Bergman et al., 1995)."}})	?P1	.	.	.	.	P3 (1||{"P3": {"Ezetimibe": "NCT00092820"}})	P4 (1||{"P4": {"Ezetimibe": "NDA021445"}})	.
Endothelin ET-A receptor	Human/Protein	Bosentan	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"BQ 123": "PMID: 9241091||We were able to perform the ﬁrst human pharmacology studies with an inhibitor of endothelin generation, phosphoramidon, in 1992 and with an endothelin receptor antagonist, BQ-123,in 1993.; https://en.wikipedia.org/wiki/BQ-123||BQ-123 is a selective ETA endothelin receptor antagonist."}})	?P1	P1 (1||{"P1": {"Bosentan": "NCT00001527; PMID: 8197152; PMID: 12070534; PMID: 8951932||Bosentan, a specific mixed antagonist of endothelin receptors with no vasoconstrictor activity, inhibits neurogenic plasma extravasation (NPE) within rat dura mater. This would predict efficacy in aborting migraine attacks, without causing cardiovascular side-effects. We investigated the efficacy of 250 mg i.v. bosentan in a randomized, double-blind, placebo-controlled, clinical trial."}})	P1 (1||{"P1": {"Bosentan": "NCT00001527"}})	P1 (1||{"P1": {"Bosentan": "NCT00001527"}})	P2 (2||{"P1": {"Bosentan": "NCT00001527"}, "P2": {"Tezosentan": "NCT02223494"}})	P2 (3||{"P1": {"Bosentan": "NCT00001527"}, "P2": {"BQ 123": "NCT00759408", "Tezosentan": "NCT02223494"}})	P2 (3||{"P1": {"Bosentan": "NCT00001527"}, "P2": {"BQ 123": "NCT00759408", "Tezosentan": "NCT02223494"}})	P4 (4||{"P3": {"A 147627": "NCT00036543", "Tezosentan": "https://www.medscape.com/viewarticle/783919"}, "P4": {"Bosentan": "NDA021290"}, "P2": {"BQ 123": "NCT00759408"}})	.	.
Peroxisome proliferator-activated receptor gamma	Human/Protein	Troglitazone	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2 (1||{"P2": {"Pioglitazone": "PMID: 7935656||Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone. In 18 nondiabetic obese subjects, 9 of whom had impaired glucose tolerance."}})	.	.	.	.	.	P3 (1||{"P3": {"Troglitazone": "PMID: 16362281||August 1996 that troglitazone ‘offered very little significant therapeutic advantage’ over existing therapies for diabetes, and later expressed his concern over the high rates of liver injury and heart failure (16 vs 7% in controls for the latter complication) reported by two Phase III trials"}})	P4 (1||{"P4": {"Troglitazone": "NDA020720"}})	.	.	.	.	.	.
Interleukin-2 receptors	Human/Protein	Denileukin diftitox	Protein drug	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"DAB486IL-2": "PMID: 1674015||DAB486IL-2 is being evaluated in phase I clinical trials in patients with chemotherapy-resistant malignancies expressing IL-2-receptor (1990)."}})	?P1	.	.	.	P1/P2 (1||{"P1/P2": {"Daclizumab": "NCT00002681"}})	P1/P2 (1||{"P1/P2": {"Daclizumab": "NCT00002681"}})	P1/P2 (1||{"P1/P2": {"Daclizumab": "NCT00002681"}})	P1/P2 (2||{"P1/P2": {"Daclizumab": "NCT00002681"}, "P1": {"Denileukin diftitox": "PMID: 9427692"}})	P4 (2||{"P4": {"Daclizumab": "NCT00048165", "Denileukin diftitox": "BLA103767; NCT00050999; NCT00051012"}})	.	.	.	.
cGMP-specific 3',5'-cyclic phosphodiesterase	Human/Protein	Sildenafil	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Sildenafil": "PMID: 17303994; https://en.wikipedia.org/wiki/Discovery_and_development_of_phosphodiesterase_5_inhibitors#cite_note-Ravipati-22||Sildenafil was initially introduced for clinical trial in 1989."}})	?P1	.	.	.	.	.	.	.	P4 (1||{"P4": {"Sildenafil": "NDA020895"}})	.	.	.	.	.
Gastric H(+)/K(+) ATPase	Human/Protein	Omeprazole	Small molecule	Digest	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2/P3 (1||{"P2/P3": {"Omeprazole": "https://www.sciencedirect.com/topics/neuroscience/omeprazole||Phase II/III clinical trials began in 1981, but were halted for 2 years as a result of yet another toxicology scare carcinogenicity, which again proved to be a false alarm."}})	.	.	.	.	.	.	.	P4 (1||{"P4": {"Omeprazole": "NDA019810"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Cysteinyl leukotriene receptor 1	Human/Protein	Zafirlukast	Small molecule	Resp	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2 (1||{"P2": {"LY 171883": "PMID: 9895400||LY 171883, was the first leukotriene-receptor antagonist to undergo clinical trials for treatment of chronic stable asthma. Because it is no longer under development, it is not considered in this review.; PMID: 2837970||LY171883, is currently in phase 2 evaluation."}})	.	.	P1 (1||{"P1": {"Zafirlukast": "PMID: 1991926||The Effect of the Oral Leukotriene Antagonist, ICI 204,219, on Leukotriene D4 and Histamine-Induced Cutaneous Vascular Reactions in Man"}})	.	.	P2 (1||{"P2": {"Zafirlukast": "PMID: 8087328||Effects of 6 Weeks of Therapy With Oral Doses of ICI 204,219, a Leukotriene D4 Receptor Antagonist, in Subjects With Bronchial Asthma. ACCOLATE Asthma Trialists Group"}})	.	P4 (1||{"P4": {"Zafirlukast": "NDA020547"}})	.	.	.	.	.	.	.
Cannabinoid receptor 1	Human/Protein	Dronabinol	Small molecule	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Delta-9-tetrahydrocannabinol": "PMID: 1099449||Oral delta-9-tetrahydrocannabinol was compared with placebo in a controlled, randomized, \"double-blind\" experiment. All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin.; PMID: 4380598"}})	?P1	.	.	.	.	.	.	P2 (1||{"P2": {"Levonantradol": "PMID: 6309451||Levonantradol: A Synthetic Cannabinoid in the Treatment of Severe Chemotherapy-Induced Nausea and Vomiting Resistant to Conventional Anti-Emetic Therapy"}})	.	P4 (1||{"P4": {"Dronabinol": "NDA018651"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Cannabinoid receptor 2	Human/Protein	Dronabinol	Small molecule	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Delta-9-tetrahydrocannabinol": "PMID: 1099449||Oral delta-9-tetrahydrocannabinol was compared with placebo in a controlled, randomized, \"double-blind\" experiment. All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin.; PMID: 4380598"}})	?P1	.	.	.	.	.	.	P2 (1||{"P2": {"Levonantradol": "PMID: 6309451||Levonantradol: A Synthetic Cannabinoid in the Treatment of Severe Chemotherapy-Induced Nausea and Vomiting Resistant to Conventional Anti-Emetic Therapy"}})	.	P4 (1||{"P4": {"Dronabinol": "NDA018651"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Prostaglandin F2-alpha receptor	Human/Protein	Latanoprost	Small molecule	Opht	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"PGF2-alpha isopropyl ester": "PMID: 11328719||In the first clinical trial with PGF2α-IE, which had the character of a pilot test, no or a minimal IOP-reducing effect was observed in patients with glaucoma.; PMID: 2751973||Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes. Presented at the 7th International Congress of Eye Research held in Nagoya 25 September - 1 October 1986, and at the International Symposium on Prostaglandins and Related Compounds in Ophthalmology held in Tokyo 2-3 October 1986."}})	?P1	.	.	.	.	P3 (1||{"P3": {"Latanoprost": "NCT00751049; NCT00751062"}})	P3 (1||{"P3": {"Latanoprost": "NCT00751049; NCT00751062"}})	.	.	P4 (1||{"P4": {"Latanoprost": "NDA020597"}})	.	.	.	.	.	.	.
DNA topoisomerase 2-alpha	Human/Protein	Doxorubicin	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Daunomycin": "PMID: 4290058||The initial clinical trials of daunomycin were begun at the National Cancer Institute in Milan, Italy. Twenty patients with different forms of cancer received the drug, 16 intravenously and 4 intra-arterially.(1964)"}})	?P1	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Doxorubicin": "NDA050467"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Substance-P receptor	Human/Protein	Aprepitant	Small molecule	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2 (1||{"P2": {"Aprepitant": "PMID: 16918326||RP-100893 (dapitant) was developed up to phase II for the treatment of migraine (1994), but then discontinued.; PMID: 12662184"}})	.	.	.	.	P1 (1||{"P1": {"Figopitant": "NCT02199899; NCT02203487"}})	P1 (1||{"P1": {"Figopitant": "NCT02203487"}})	P3 (1||{"P3": {"Aprepitant": "NCT00035048"}})	P3 (2||{"P3": {"Aprepitant": "NCT00035048; NCT00042029; NCT00092196"}, "P2": {"GW 597599": "NCT00048204"}})	P4 (2||{"P4": {"Aprepitant": "NDA021549"}, "P2": {"GW 597599": "NCT00048204"}})
NMDA receptor	Human/Protein	Memantine	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	P2 (1||{"P2": {"Memantine": "NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00000867; NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00000867; NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00000867; NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00000867; NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00000867; NCT00001344"}})	P2 (1||{"P2": {"Memantine": "NCT00000867; NCT00001344"}})	.	P4 (1||{"P4": {"Memantine": "NDA021487"}})
4-hydroxyphenylpyruvate dioxygenase	Human/Protein	Nitisinone	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Nitisinone": "PMID: 28769581||The first clinical use of nitisinone in HT-1 dates back to 1991. (HT-1 only has one target-4-hydroxyphenylpyruvate dioxygenase and one drug Nitisinone. )"}})	?P1	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Nitisinone": "NDA021232"}})	.
cGMP-inhibited 3',5'-cyclic phosphodiesterase	Human/Protein	Anagrelide hydrochloride	Small molecule	Hema	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Cilostazol": "PMID: 11830753||In the early 1980s, the potent antiplatelet (83) and vasodilatory effects (49,82) of cilostazol were demonstrated in clinical studies on various diseases.; PMID: 4074434"}})	?P1	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Anagrelide hydrochloride": "NDA020333"}})	.	.	.	.	.	.
Low affinity immunoglobulin epsilon Fc receptor	Human/Protein	Omalizumab	Antibody	Resp	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Omalizumab": "https://en.wikipedia.org/wiki/Omalizumab#History||In 1991, after several rounds of pre-IND (\"investigational new drug\"; PMID: 9062345) meetings with officials/scientists of the FDA, the FDA finally gave a nod for CGP51901 to be tested in human subjects.; PMID:9062345||In 1991-1993, researchers from Ciba-Geigy and Tanox and a leading clinical research group (headed by Stephen Holgate) in the asthma/allergy field ran a successful Phase I human clinical trial of CGP51901 in Southampton, England and showed that the tested antibody is safe."}})	?P1	.	.	.	.	.	.	.	.	.	P3 (2||{"P3": {"Omalizumab": "NCT00232050"}, "P1": {"ST 152": "NCT00046488"}})	P4 (2||{"P4": {"Omalizumab": "BLA103976"}, "P1": {"ST 152": "NCT00046488"}})
Acetylcholinesterase	Human/Protein	Tacrine hydrochloride	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Tacrine hydrochloride": "Schneider, Lon S. Tacrine Development Experience: Early Clinical Trials and Enrichment and Parallel Designs.[J]. Alzheimer Disease & Associated Disorders, 1994, 8(2):S12-S21.||The smaller-scale tacrine trials are summarized in Table 1 (the smaller-scale tacrine are summarized in table 1 (Summers et al., 1981,)(12person))"}})	?P1	.	.	.	.	.	.	.	.	P2 (1||{"P2": {"Tacrine hydrochloride": "PMID: 1781288||[Drug Evaluation of Huperzine A in the Treatment of Senile Memory Disorders]"}})	.	P4 (2||{"P1": {"Rivastigmine tartrate": "PMID: 8424849"}, "P4": {"Tacrine hydrochloride": "NDA020070"}})	.	.	.	.	.	.	.	.	.	.
Prostacyclin receptor	Human/Protein	Epoprostenol sodium	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Epoprostenol sodium": "NCT00004754; PMID: 6130330||A 96h infusion of epoprostenol (prostacyclin) or placebo was given as a treatment for rest pain to 28 patients with severe peripheral arterial disease."}})	?P1	.	.	.	P2 (1||{"P2": {"Epoprostenol sodium": "PMID: 3292596||Epoprostenol (Prostacyclin) in Unstable Angina"}})	.	.	.	.	.	.	P4 (2||{"P4": {"Epoprostenol sodium": "NDA020444"}, "P3": {"Iloprost": "NCT00004786"}})	.	.	.	.	.	.	.	.
Follicle stimulating hormone	Human/Protein	Follitropin alpha	Protein drug	Genit	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Purified urinary follicle-stimulating hormone": "PMID: 3919586||Purified urinary follicle-stimulating hormone was used to induce ovulation in 18 patients with polycystic ovarian syndrome."}})	?P1	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Follitropin alpha": "NDA020582"}})	.	.	.	.	.	.
CAMPATH-1 antigen	Human/Protein	Alemtuzumab	Antibody	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Alemtuzumab": "https://doi.org/10.1016/B978-0-12-384929-8.00081-2||A fully reshaped humanized version, Campath-1H (human IgG1), was derived by genetic engineering (Riechmann et al., 1988) and is marketed as alemtuzuma (Lemtrada®).; PMID: 2904526||A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. Lancet. 1988 Dec 17."}})	?P1	.	.	.	.	.	.	.	.	.	P2 (1||{"P2": {"Alemtuzumab": "NCT00001984"}})	P2 (1||{"P2": {"Alemtuzumab": "NCT00001984"}})	P4 (1||{"P4": {"Alemtuzumab": "BLA103948"}})	.	.
L-type calcium channel	Human/Protein	Verapamil hydrochloride	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Verapamil hydrochloride": "PMID: 4969551||A controlled double-blind study of verapamil in 16 anginal patients used two dose levels—40 mg. t.d.s. and 120 mg. t.d.s.—and was compared with propranolol 100 mg. t.d.s."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Verapamil hydrochloride": "NDA018485"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Aromatase	Human/Protein	Anastrozole	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	P2 (1||{"P2": {"Testolactone": "NCT00001181; PMID: 4884063||Three hundred and nineteen women with advanced and metastatic carcinoma of the breast were treated according to the protocol of the Cooperative Breast Cancer Group with one of three compounds: Δ1‐testololactone, micronized medroxy progesterone acetate or oxylone acetate. The National Cancer Institute has been working with the Cooperative Breast Cancer Group since 1957 to develop potent anticancer agents with minimal undesirable qualities and many steroids have been evaluated clinically in this program."}})	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Anastrozole": "NDA020541"}})	.	.	.	.	.	.	.	.
Voltage-gated sodium channel	Human/Protein	Lamotrigine	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Zonisamide": "PMID: 15511695||In the United States, clinical trials of zonisamide began in the early1980s."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	P2 (1||{"P2": {"Lamotrigine": "PMID: 8232944"}})	P4 (1||{"P4": {"Lamotrigine": "NDA020241"}})	.	.	.	.	.	.	.	.	.
ATP-binding cassette sub-family C member 8	Human/Protein	Glibenclamide	Small molecule	Metabo	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Glibenclamide": "PMID: 4898091||Clinical trial of a new sulphonylurea in maturity-onset diabetes--HB419 (glibenclamide)."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Glibenclamide": "NDA017532"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Prostaglandin G/H synthase 2	Human/Protein	Diclofenac sodium	Small molecule	Bone	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1/P2 (1||{"P1/P2": {"Ketoprofen": "PMID: 796936||Zutshi and colleagues (1973) compared ketoprofen 75 mg (rising to 100 mg) daily with a placebo in a double-blind study, involving 50 patients with rheumatoid arthritis"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Diclofenac sodium": "NDA019201"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
P2Y purinoceptor 12	Human/Protein	Ticlopidine hydrochloride	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Ticlopidine hydrochloride": "PMID: 1100310||The effect of this drug was studied on 55 subjects, healthy volunteers and hospitalized patients. The action requires 24 to 48 hr to appear, and lasts more than 3 days. A dose-effect relationship was studied with oral daily doses ranging from 250 to 1,000 mg during 1 wk; it showed a 50% inhibition on adenosine diphosphate (ADP )-induced aggregation at 2 f.LM concentration on an oral daily dose of 450 mg."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Ticlopidine hydrochloride": "NDA019979"}})	.	.	.	.	.	.	.	.	.	.	.	.
Epidermal growth factor receptor	Human/Protein	Gefitinib	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2 (1||{"P2": {"EMD 55900": "NCT00589706"}})	.	.	.	.	.	.	.	.	.	P3 (1||{"P3": {"Omacor": "NCT01422317"}})	P3 (1||{"P3": {"Omacor": "NCT01422317"}})	P3 (1||{"P3": {"Omacor": "NCT01422317"}})	P3 (1||{"P3": {"Omacor": "NCT01422317"}})	P3 (3||{"P1": {"BIBX 1382": "NCT00003980", "Gefitinib": "NCT00005806"}, "P3": {"Omacor": "NCT01422317"}})	P3 (3||{"P3": {"Gefitinib": "NCT00034879; NCT00635973", "Omacor": "NCT01422317"}, "P1": {"Panitumumab": "NCT00004879"}})	P3 (4||{"P3": {"Erlotinib hydrochloride": "NCT00036647; NCT00047736", "Gefitinib": "NCT00034879; NCT00635973", "Omacor": "NCT01422317"}, "P1": {"Panitumumab": "NCT00004879"}})	P3 (5||{"P2": {"Cetuximab": "NCT00044863", "Panitumumab": "NCT00039273"}, "P3": {"Erlotinib hydrochloride": "NCT00036647; NCT00047736; NCT00633750", "Gefitinib": "NCT00034879; NCT00049543; NCT00635973", "Omacor": "NCT01422317"}})	P4 (6||{"P2": {"Cetuximab": "NCT00044863; NCT00055419", "EMD 72000": "NCT00073541", "Panitumumab": "NCT00039273"}, "P3": {"Erlotinib hydrochloride": "NCT00036647; NCT00047736; NCT00633750"}, "P4": {"Gefitinib": "NDA021399"}, "P1/P2": {"HuMax-EGFR": "NCT00093041"}})
T-type calcium channel	Human/Protein	Zonisamide	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Zonisamide": "PMID: 15511695||In the United States, clinical trials of zonisamide began in the early1980s."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Zonisamide": "NDA020789"}})	.	.	.
Estrogen receptor	Human/Protein	Tamoxifen Citrate	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"MER 25": "doi:10.1001/jama.1963.73700240008012||MER-25, an antiestrogen as tested on animals,11 was first released for clinical trials in 1957 and administered to postmenopausal women with cancer of the breast and endometrium; PMID: 2194650"}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Tamoxifen Citrate": "NDA017970"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Antithrombin-III	Human/Protein	Enoxaparin	Small molecule	Circul	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2 (1||{"P2": {"Enoxaparin": "PMID: 4568221||Heparin treatment reduced the rate of venous thrombosis from 19 of 118 patients (16.1 per cent) to two of 108 (1.9 per cent) treated after elective surgery, from 11 of 23 untreated (48 per cent) to three of 23 (13 per cent) treated after hip fracture, and from nine of 40 (22.5 per cent) to one of 38 (2.6 per cent) treated patients admitted to the hospital for suspected myocardial infarction. Thrombosis occurred in 21.5 per cent of the total of 181 untreated and in 3.6 per cent of 169 heparin-treated patients."}})	.	.	.	.	.	.	.	.	.	.	P3 (1||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)"}})	P3 (1||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)"}})	P3 (1||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)"}})	P3 (1||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)"}})	P3 (2||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)", "Unfractionated heparin": "PMID: 2905187||Comparison of a Low Molecular Weight Heparin and Unfractionated Heparin for the Prevention of Deep Vein Thrombosis in Patients Undergoing Abdominal Surgery. The European Fraxiparin Study (EFS) Group"}})	P3 (1||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)"}})	P3 (1||{"P3": {"Enoxaparin": "PMID: 1963022||Prevention of Thromboembolic Disease in General Surgery With Enoxaparin (Clexane)"}})	.	P2 (1||{"P2": {"Enoxaparin": "PMID: 1329919||The Low Molecular Weight Heparin Enoxaparin Inhibits the Consumption of Factor VII and Prothrombin Activation in Vivo Associated With Elective Knee Replacement Surgery"}})	P4 (2||{"P4": {"Enoxaparin": "FDA; NDA020164"}, "P3": {"Tinzaparin sodium": "NCT00628576"}})	.	.	.	.	.	.	.	.	.	.
DNA topoisomerase 1	Human/Protein	Irinotecan	Small molecule	Cancer	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Camptothecin": "PMID 1312588||Topotecan is the first topoisomerase I-targeting agent to enter clinical development in the United States since studies of sodium camptothecin over 2 decades ago.; PMID 5081595||During the late 1960s, phase I trials of the parent drug, sodium camptothecin, demonstrated objective antineoplastic activity against gastrointestinal adenocarcinoma, melanoma, non-small cell lung cancer, and acute myelogenous leukemia.; PMID 5081595||Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Topotecan": "NCT00001333; NCT00002537"}})	P1 (1||{"P1": {"Topotecan": "NCT00001333; NCT00002537"}})	P2 (3||{"P2": {"IDEC 132": "NCT00001427; NCT00251368"}, "P1": {"Irinotecan": "NCT00001495", "Topotecan": "NCT00001333; NCT00002537; NCT00002625"}})	P4 (3||{"P2": {"IDEC 132": "NCT00001427; NCT00251368"}, "P4": {"Irinotecan": "NDA020571", "Topotecan": "NDA020671"}})	.	.	.	.	.	.	.
Catechol O-methyltransferase	Human/Protein	Tolcapone	Small molecule	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"GPA 1714": "PMID: 1103160||Of additional interest is the fact that GPA-1714 has sedative effects on animals but has no antihistaminic or anticholinergic effects. Because of these wide-ranging implications, a clinical trial of GPA-1714 was undertaken to assess its possible activity and safety. Eleven male patients were selected from the research wards, The trial began with a four-week drug-free period during which placebo.; PMID: 4561199"}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P2 (1||{"P2": {"Entacapone": "PMID: 9392574"}})	P4 (2||{"P2": {"Entacapone": "PMID: 9818851"}, "P4": {"Tolcapone": "NDA020697"}})	.	.	.	.	.
Plasminogen	Human/Protein	Alteplase	Protein drug	Nerve	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Streptokinase": "PMID: 17948083||In 1958, Sherry and others started using streptokinase in patients with acute myocardial infarction and changed the focus of treatment from palliation to \"cure\"."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P3 (1||{"P3": {"Streptokinase": "NCT00000503||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries"}})	P3 (1||{"P3": {"Streptokinase": "NCT00000503||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries"}})	P3 (1||{"P3": {"Streptokinase": "NCT00000503||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries"}})	P3 (1||{"P3": {"Streptokinase": "NCT00000503||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries"}})	P3 (1||{"P3": {"Streptokinase": "NCT00000503||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries"}})	P4 (2||{"P4": {"Alteplase": "BLA103172"}, "P3": {"Streptokinase": "NCT00000503||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Carbonic anhydrase 2	Human/Protein	Dorzolamide hydrochloride	Small molecule	Opht	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Chlorothiazide": "PMID:14477425||Ten healthy male subjects were subjected to a controlled double blind study to test the hypothesis that the efficacy of chlorothiazide is a function of dosage regimen phase1 1961."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P2 (1||{"P2": {"Dorzolamide hydrochloride": "PMID: 8406063||Two Topical Carbonic Anhydrase Inhibitors Sezolamide and Dorzolamide in Gelrite Vehicle: A Multiple-Dose Efficacy Study"}})	P4 (1||{"P4": {"Dorzolamide hydrochloride": "NDA020408"}})	.	.	.	.	.	.	.	.	.
Peroxisome proliferator-activated receptor alpha	Human/Protein	Clofibrate	Small molecule	Metabo	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"2-phenylbutyric acid": "https://en.wikipedia.org/wiki/Fibrate||Although used clinically since the 1930s, if not earlier, the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), especially PPARα.; PMID: 20393155||The first fibrates were synthesized in the mid-1950s. Their clinical development came from the observation, in 1953, of researchers in France that, among 80 synthesized structures derived from dehydrocholic acid, phenylethyl acetic acid and certain other disubstituted acetic acids exhibited hypocholesterolemic properties in rats and humans.; PMID: 13141149||Clinical trials on the hypocholesteremia-producing effect of 2-phenylbutyric acid."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Clofibrate": "NDA016099"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Tumor necrosis factor	Human/Protein	Etanercept	Protein drug	Bone	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Thalidomide": "PMID: 18332230||Chemie Gru¨nenthal, a German pharmaceutical company, introduced thalidomide (N-[phthalimido] glutarimide) into the market as a sedative on October 1, 1957."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P2/P3 (2||{"P2/P3": {"Infliximab": "NCT00269854"}, "P2": {"Thalidomide": "NCT00001446"}})	P2/P3 (2||{"P2/P3": {"Infliximab": "NCT00269854"}, "P2": {"Thalidomide": "NCT00001446"}})	P2/P3 (2||{"P2/P3": {"Etanercept": "NCT03780959"}, "P2": {"Thalidomide": "NCT00001446"}})	P4 (4||{"P4": {"Etanercept": "BLA103795", "Infliximab biosimilar IXIFI": "BLA103772", "Infliximab": "BLA103772", "Thalidomide": "NDA020785"}})	.	.	.	.	.
Histamine H1 receptor	Human/Protein	Terfenadine	Small molecule	Immu	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Antergan": "PMID: 10444205; https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2222.1999.00004.x-i1||The paper provides a historical overview of the discovery of both histamine and the H1 antihistamines. This compound antergan (N1N dimethyl‐N1‐benzyl‐N‐phenyl‐ethylenediamine), described by Halpern in 1942 was the first antihistamine used clinically in man.; Halpern B N. Les antihistaminiques de synthèse: Essai de chimiothérapie des états allergiques[J]. 1942, 68:339-408."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Terfenadine": "FDA"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Insulin	Human/Protein	Insulin Human	Protein drug	Metabo	P1 (1||{"P1": {"Insulin Human": "PMID: 25429881||However, it was not until 1921 that insulin was purified, which was used to treat diabetes in 1922. "}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Insulin Human": "NDA018780"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Bacterial penicillin-binding proteins	Non-Human/Protein	Penicillin	Small molecule	Infection	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Penicillin": "PMID: 3511336||But, as this paper shows, penicillin was used therapeutically and successfully, as a local application, as early as 1930. Three claims that penicillin had been used effectively on patients around that time have arisen from work by Fleming himself, C.G. Paine, and A. Dickson Wright, but until now no claim has been substantiated by documented clinical notes."}})	?P1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P4 (1||{"P4": {"Penicillin": "ANDA060074"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Bacterial DNA topoisomerase IV	Non-Human/Protein	Nalidixic acid	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Nalidixic acid": "PMID 12702699||The discovery of nalidixic acid in 1962, and its introduction for clinical use in 1967, marks the beginning of five decades of quinolone development and use.; https://en.wikipedia.org/wiki/Nalidixic_acid||Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a byproduct of chloroquine manufacture in the 1960s.Used clinically from 1967."}})	P1 (1||{"P1": {"Nalidixic acid": "PMID: 14058206||The data on previous bacteriological, toxicological, and pharmacological studies obtained at the Sterling Winthrop Research Institute have been summarized by Lishman and Swinney (1963)."}})	P4 (1||{"P4": {"Nalidixic acid": "NDA014214"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Bacterial DNA gyrase	Non-Human/Protein	Nalidixic acid	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Nalidixic acid": "PMID 12702699||The discovery of nalidixic acid in 1962, and its introduction for clinical use in 1967, marks the beginning of five decades of quinolone development and use.; https://en.wikipedia.org/wiki/Nalidixic_acid||Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a byproduct of chloroquine manufacture in the 1960s.Used clinically from 1967."}})	P1 (1||{"P1": {"Nalidixic acid": "PMID: 14058206||The data on previous bacteriological, toxicological, and pharmacological studies obtained at the Sterling Winthrop Research Institute have been summarized by Lishman and Swinney (1963)."}})	P4 (1||{"P4": {"Nalidixic acid": "NDA014214"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DNA-dependent RNA polymerase	Non-Human/Protein	Rifampin	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Rifampin": "PMID: 5322667"}})	?P1	.	.	.	P4 (1||{"P4": {"Rifampin": "NDA050420"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Reverse transcriptase/ribonuclease H 	Non-Human/Protein	Zidovudine	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Zidovudine": "PMID: 2869302||In a 6-week clinical trial 4 dose regimens of 3’-azido-3’-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDSrelated complex (ARC)."}})	?P1	P4 (1||{"P4": {"Zidovudine": "NDA019655"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Polymerase/reverse transcriptase domain (RT)	Non-Human/Protein	Lamivudine	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Lamivudine": "PMID: 1283519||The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study."}})	?P1	.	P4 (1||{"P4": {"Lamivudine": "NDA020564"}})	.	.	.	.	.	.	.	.
Neuraminidase	Non-Human/Protein	Zanamivir	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Zanamivir": "PMID: 10711940||Inhaled zanamivir entered clinical trials in 1994. The first orally active inhibitor, oseltamivir, was described by Kim and colleagues in 1997; A second oral agent (RWJ270201, BCX-1812) entered clinical trials in 1999. The first inhibitors of influenza virus neuraminidase (NA), developed by P Meindl and H Tuppy in 1969, inhibited viral replication but had low potency and specificity.; https://en.wikipedia.org/wiki/Discovery_and_development_of_neuraminidase_inhibitors#cite_note-christ-1||Then it was found that the synthetic compound 2-deoxy-2,3-didehydro-N-acetylneuraminic acid(Neu5Ac2en or DANA) which is an analogue of N-acetylneuraminic acid (Neu5Ac), inhibits the release of virus progeny in tissue culture but no antiviral activity in animals was detected."}})	?P1	P2 (1||{"P2": {"Relenza IV": "PMID: 8544269||Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza"}})	.	P3 (1||{"P3": {"Relenza IV": "PMID: 9863784||Randomised Trial of Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group"}})	P4 (1||{"P4": {"Zanamivir": "NDA021036"}})	.	.	.	.
1,3-beta-d-glucan synthase	Non-Human/Protein	Caspofungin	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Caspofungin": "PMID: 21925846||Clinical studies with CAS were first initiated in 1995."}})	?P1	.	P1 (1||{"P1": {"Micafungin": "NCT00001790"}})	P3 (1||{"P3": {"Micafungin": "NCT00001937; NCT00036166; NCT00036179"}})	P3 (2||{"P3": {"Caspofungin": "NCT00008359", "Micafungin": "NCT00001937; NCT00036166; NCT00036179"}})	P4 (3||{"P2": {"Anidulafungin": "NCT00037219", "Micafungin": "NCT00036166; NCT00036179"}, "P4": {"Caspofungin": "NDA021227"}})	.	.
Pyruvate dehydrogenase [NADP(+)]	Non-Human/Protein	Nitazoxanide	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Nitazoxanide": "PMID: 11362906||A phase I/II dose-ranging study of nitazoxanide (NTZ; NCT00002444), a new drug for cryptosporidiosis, is opening this month at Cornell/New York Hospital."}})	P1 (1||{"P1": {"Nitazoxanide": "NCT00002444"}})	.	P2/P3 (1||{"P2/P3": {"Nitazoxanide": "NCT00001081||A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium"}})	.	P3 (1||{"P3": {"Nitazoxanide": "NCT00004986||Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients"}})	.	P4 (1||{"P4": {"Nitazoxanide": "NDA021498"}})	.
Transmembrane protein gp41	Non-Human/Protein	Enfuvirtide	Protein drug	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Enfuvirtide": "PMID: 9809555||Here we report the results of the first clinical trial, to our knowledge, examining the safety, pharmacokinetics and anti-retroviral activity of T-20 administered intravenously to HIV-infected humans."}})	P2 (1||{"P2": {"Enfuvirtide": "NCT00002239||A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults"}})	.	.	.	P4 (1||{"P4": {"Enfuvirtide": "NDA021481"}})
Bacterial 50S ribosome subunit	Non-Human/Non-Protein	Erythromycin	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Erythromycin": "U.S. Patent: US2653899"}})	P4 (1||{"P4": {"Erythromycin": "PMID: 14947931"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Bacterial cell membrane	Non-Human/Non-Protein	Chlorhexidine	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Chlorhexidine": "PMID: 18171263"}})	.	.	.	.	P4 (1||{"P4": {"Chlorhexidine": "https://drugs.ncats.io/drug/R4KO0DY52L"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DNA polymerase catalytic subunit	Non-Human/Protein	Acyclovir	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Acyclovir": "PMID: 91931||ACYCLOVIR FOR TREATMENT OF MUCOCUTANEOUS HERPES INFECTION IN A CHILD WITH LEUK&AElig;MIA"}})	?P1	.	P4 (1||{"P4": {"Acyclovir": "NDA018604"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Lanosterol 14-alpha demethylase	Non-Human/Protein	Fluconazole	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1/P2 (2||{"P1": {"Fluconazole": "PMID: 3004323"}, "P1/P2": {"Itraconazole": "NCT00004811||Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis"}})	.	.	.	P3 (1||{"P3": {"Fluconazole": "PMID: 2539186||A Comparison of Single-Dose Oral Fluconazole With 3-day Intravaginal Clotrimazole in the Treatment of Vaginal Candidiasis. Report of an International Multicentre Trial"}})	P4 (1||{"P4": {"Fluconazole": "NDA019949"}})	.	.	.	.	.	.	.	.	.	.	.	.	.
Protease	Non-Human/Protein	Saquinavir mesylate	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	P1 (1||{"P1": {"Saquinavir mesylate": "NCT02184286; PMID:7840913||There are several proteinase inhibitors in development; the first to enter clinical trials was saquinavir.Three clinical studies involving a total of 202 patients treated with saquinavir have been conducted in the United Kingdom, France and Italy during 1992-1993."}})	?P1	P2 (1||{"P2": {"Saquinavir mesylate": "NCT00001040||Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC"}})	P4 (3||{"P1": {"Indinavir sulfate": "NCT00001443"}, "P1/P2": {"Ritonavir": "PMID: 7477167"}, "P4": {"Saquinavir mesylate": "NDA020628"}})	.	.	.	.	.	.	.	.
Fungal fumarate reductase	Non-Human/Protein	Thiabendazole	Small molecule	Infection	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	?P1	?P1	P2 (1||{"P2": {"Thiabendazole": "PMID: 5324370||Thiabendazole was administered orally to 40 ancylostomiasis patients at 50 mg. per kg. body-weight as a suspension or as chewable tablets. With the suspension, over 80% reduction in egg counts occurred in 6 of 16 cases."}})	P4 (1||{"P4": {"Thiabendazole": "NDA016096"}})	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
